Related Experiment Video
Updated: Apr 10, 2026

RNA Pull-down Procedure to Identify RNA Targets of a Long Non-coding RNA
Published on: April 10, 2018
Long noncoding RNA AC007637.1 inhibits tumorigenesis by regulating the Trim25/PCNA axis in colorectal cancer
Xue Wang1, Jiuming Li1, Chu Hao2
1Wuxi Cancer Institute, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu 214062, China; Laboratory of Cancer Epigenetics, Wuxi School of Medicine, Jiangnan University, Wuxi, Jiangsu 214122, China.
Introduction:
Mounting evidence indicates that long noncoding RNAs (lncRNAs) play crucial roles in tumorigenesis and progression.
Objectives:
This study aimed to elucidate the role of AC007637.1, a lncRNA downregulated in colorectal cancer (CRC) identified by our previous transcriptomic analyses.
Methods:
AC007637.1 expression in CRC was assessed via bioinformatic analysis and qRT-PCR. The effects of AC007637.1 on CRC tumorigenesis were evaluated using CCK-8 assays, colony formation assays and tumor xenograft models. RNA immunoprecipitation, RNA pull-down, and co-immunoprecipitation assays were utilized to clarify the molecular mechanism of AC007637.1 in CRC.
Results:
AC007637.1 serves as a tumor suppressor by inhibiting CRC proliferation and tumorigenicity. It directly binds to proliferating cell nuclear antigen (PCNA) and promotes Tripartite motif-containing 25 (Trim25)-mediated PCNA ubiquitination and subsequent proteasomal degradation, thereby inhibiting DNA replication and repair pathways and enhancing cancer cell sensitivity to DNA-damage-related therapies. In addition, the stability of AC007637.1 is reduced by fragile X-related protein-1 (FXR1) and its transcription is inhibited by promoter hypermethylation.
Conclusions:
We identify a novel AC007637.1/Trim25/PCNA regulatory axis in CRC, providing valuable insights into the molecular pathogenesis of this disease. This axis represents apromising therapeutic target for CRC.
Insights
This study reveals long noncoding RNA AC007637.1 acts as a tumor suppressor in colorectal cancer (CRC). It inhibits cancer growth by targeting the PCNA protein, offering a potential new therapeutic strategy for CRC.
Area of Science:
- Molecular Biology
- Cancer Research
- Genetics
Background:
- Long noncoding RNAs (lncRNAs) are increasingly recognized for their roles in cancer development.
- Colorectal cancer (CRC) progression is influenced by various genetic and epigenetic factors.
- Previous transcriptomic analyses identified AC007637.1 as a downregulated lncRNA in CRC.
Purpose of the Study:
- To investigate the function of the lncRNA AC007637.1 in colorectal cancer.
- To elucidate the molecular mechanisms underlying AC007637.1's role in CRC pathogenesis.
- To evaluate AC007637.1 as a potential therapeutic target for CRC.
Main Methods:
- Assessed AC007637.1 expression using bioinformatic analysis and qRT-PCR.
- Evaluated the impact of AC007637.1 on CRC cell proliferation and tumor growth in vitro and in vivo.
- Utilized molecular assays (RIP, pull-down, co-IP) to determine the interaction between AC007637.1, PCNA, and Trim25.
Main Results:
- AC007637.1 functions as a tumor suppressor, inhibiting CRC cell proliferation and tumorigenicity.
- AC007637.1 directly binds to PCNA, promoting its ubiquitination and degradation via Trim25.
- This interaction inhibits DNA replication/repair, sensitizing cancer cells to DNA-damage therapies; FXR1 reduces AC007637.1 stability, and hypermethylation inhibits its transcription.
Conclusions:
- Identified a novel AC007637.1/Trim25/PCNA regulatory axis critical to CRC molecular pathogenesis.
- AC007637.1 acts as a tumor suppressor by destabilizing PCNA.
- This regulatory axis presents a promising therapeutic target for colorectal cancer treatment.
Related Concept Videos
lncRNA - Long Non-coding RNAs
lncRNA - Long Non-coding RNAs
MicroRNAs
MicroRNAs
Experimental RNAi
Non-LTR Retrotransposons